Trial Profile

A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gebasaxturev (Primary) ; Gebasaxturev (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

19 Sep 2024 This trial has been completed in Spain (Global end date: 2023-07-17) according to European Clinical Trials Database record.
01 Mar 2024 Status changed from completed to discontinued.
24 Jan 2024 This trial has been Completed in Germany, According to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com